Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 · View on ClinicalTrials.gov ↗
Study Summary
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG PF-08046054
Study Locations (20)
Texas
- University of Texas Southwestern Medical Center - Simmons Cancer Center — Dallas
- UT Southwestern Medical Center - Redbird — Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital — Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital — Dallas
- University Of Texas Southwestern Medical Center — Dallas
- UT Southwestern - Simmons Cancer Center - Fort Worth — Fort Worth
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services — Houston
- The University of Texas MD Anderson Cancer Center — Houston
Alabama
- University of Alabama at Birmingham — Birmingham
- University of Alabama at Birmingham, IDS Pharmacy — Birmingham
- University of Alabama at Birmingham — Birmingham
- University of Alabama at Birmingham — Birmingham
California
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange
- University of California Davis Comprehensive Cancer Center — Sacramento
- University of California, Davis Medical Center — Sacramento
Michigan
- Karmanos Cancer Institute — Detroit
- Karmanos Cancer Institute — Farmington Hills
Iowa
- University of Iowa — Iowa City
Ohio
- University Hospitals Cleveland Medical Center — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2029-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05208762
The ClinicalTrials.gov registry entry for NCT05208762 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 8 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions — of which pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05208762 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Texas, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05208762 about?
NCT05208762 is a clinical study titled "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors". This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum...
What is the current status of trial NCT05208762?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 714 participants. The study started on 2022-10-25. Estimated completion is 2029-01-04.
What conditions does trial NCT05208762 study?
This clinical trial studies the following conditions: Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Carcinoma, Non-Small-Cell Lung, Pancreatic Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05208762?
The interventions under investigation include: pembrolizumab (DRUG), PF-08046054 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05208762?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05208762 being conducted?
This trial has 20 study locations across Alabama, California, Iowa, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.